NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free LPCN Stock Alerts $4.80 +0.25 (+5.50%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$4.51▼$4.8150-Day Range$3.58▼$6.5152-Week Range$2.31▼$7.15Volume19,754 shsAverage Volume151,905 shsMarket Capitalization$25.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lipocine alerts: Email Address Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Lipocine Stock (NASDAQ:LPCN)Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More LPCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPCN Stock News HeadlinesApril 27, 2024 | americanbankingnews.comLipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.comApril 19, 2024 | americanbankingnews.comLipocine (NASDAQ:LPCN) Now Covered by StockNews.comApril 27, 2024 | DTI (Ad)My top 100 stocks…We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.April 12, 2024 | msn.comLipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAsApril 11, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | fr.investing.comLipocine annonce les résultats positifs d'une étude sur le traitement de l'obésitéApril 11, 2024 | markets.businessinsider.comLipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With ObesityApril 11, 2024 | finance.yahoo.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 27, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…April 11, 2024 | prnewswire.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityMarch 28, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 28, 2024 | markets.businessinsider.comLipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 StudyMarch 28, 2024 | prnewswire.comLipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 25, 2024 | finance.yahoo.comCirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsightMarch 25, 2024 | prnewswire.comLipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154March 7, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q4 2023March 7, 2024 | seekingalpha.comLipocine GAAP EPS of -$3.14March 7, 2024 | prnewswire.comLipocine Announces Financial Results for the Full Year Ended December 31, 2023March 6, 2024 | finance.yahoo.comLipocine to Present at 36th Annual Roth ConferenceFebruary 6, 2024 | finance.yahoo.comLipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154February 2, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity PharmaceuticalsFebruary 2, 2024 | fr.investing.comLipocine transfère la commercialisation de TLANDO à Verity PharmaFebruary 2, 2024 | finance.yahoo.comLipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsJanuary 18, 2024 | marketwatch.comLipocine Shares Rise Premarket on Tlando Licensing DealJanuary 18, 2024 | msn.comLipocine licenses Tlando testosterone therapy to Verity PharmaJanuary 18, 2024 | markets.businessinsider.comLipocine Signs TLANDO Franchise License Deal With Verity PharmaJanuary 18, 2024 | finance.yahoo.comLipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaSee More Headlines Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees17Year Founded1997Profitability EPS (Most Recent Fiscal Year)($3.0503) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.28% Return on Assets-58.27% Debt Debt-to-Equity RatioN/A Current Ratio8.69 Quick Ratio8.69 Sales & Book Value Annual Sales$500,000.00 Price / Sales51.34 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book1.25Miscellaneous Outstanding Shares5,350,000Free Float5,081,000Market Cap$25.67 million OptionableNo Data Beta1.05 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Mahesh V. Patel Ph.D. (Age 67)Co-Founder, Interim Principal Financial Officer, Director, President & CEO Comp: $598.91kMs. Krista Fogarty (Age 56)Principal Accounting Officer & Corporate Controller Comp: $268.12kDr. Nachiappan Chidambaram Ph.D. (Age 54)Senior Vice President of Research & Development Comp: $311.17kMr. Logan Morse (Age 54)Vice President of Sales, Marketing & Operations Comp: $413.58kMr. Morgan R. Brown CPA (Age 56)M.B.A., Corporate Secretary Comp: $472.45kKey CompetitorsEyenoviaNASDAQ:EYENVaxxinityNASDAQ:VAXXIterum TherapeuticsNASDAQ:ITRMUnity BiotechnologyNASDAQ:UBXSensei BiotherapeuticsNASDAQ:SNSEView All CompetitorsInsiders & InstitutionsWealth Effects LLCSold 4,122 shares on 1/29/2024Ownership: 0.275%Mahesh V PatelBought 8,706 shares on 5/25/2023Total: $43,791.18 ($5.03/share)View All Insider TransactionsView All Institutional Transactions LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed in 2024? Lipocine's stock was trading at $2.79 at the beginning of the year. Since then, LPCN shares have increased by 72.0% and is now trading at $4.7977. View the best growth stocks for 2024 here. Are investors shorting Lipocine? Lipocine saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 278,400 shares, an increase of 155.6% from the March 31st total of 108,900 shares. Based on an average daily volume of 61,900 shares, the short-interest ratio is presently 4.5 days. Approximately 5.4% of the shares of the stock are short sold. View Lipocine's Short Interest. When is Lipocine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our LPCN earnings forecast. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings results on Thursday, March, 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.11. The specialty pharmaceutical company had revenue of $0.22 million for the quarter. When did Lipocine's stock split? Lipocine's stock reverse split on the morning of Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX). How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LPCN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest MetalsMysterious Gold Leverage Just AnnouncedStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
